ArticleJAMA network open2022
Evaluation of an Optical Defocus Treatment for Myopia Progression Among Schoolchildren During the COVID-19 Pandemic.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Efficacy of spectacle lenses specifically designed for myopia control: systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Pooled it
- Interventions to improve well-being among children and youth aged 6-17 years during the COVID-19 pandemic: a systematic review.BMC medicine · 2023Pooled it
- Interaction of retinal electrophysiology and novel orthokeratology lens use on myopia control efficacy in children.The British journal of ophthalmology · 2025Trial
- Effect of virtual reality-based visual training for myopia control in children: a randomized controlled trial.BMC ophthalmology · 2024Trial
- Trial
- Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response.Scientific reports · 2022Trial
- Spectacle lenses for control of myopia progression in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Orthokeratology and retinal risk: a new dimension in myopia control.Translational pediatrics · 2026Article
- Microneedle technology in the treatment of ocular diseases: Advances and applications.Asian journal of pharmaceutical sciences · 2026Review
- Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study.Turkish journal of ophthalmology · 2026Observational
- Comparison of Seasonal Variation in Myopia Progression: Defocus Incorporated Multiple Segment Spectacle Lenses in Combination with 0.01% Atropine vs Orthokeratology.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Axial elongation among Hong Kong myopic children and adolescents wearing single vision spectacles from a clinical setting.Scientific reports · 2025Article
- Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study.Eye and vision (London, England) · 2025Article
- Real-world outcomes of Defocus Incorporated Multiple Segments lenses on retarding axial elongation in myopic children and adolescents.Frontiers in medicine · 2024Article
- Size of living space as a moderator for central and peripheral refractions in children.Scientific reports · 2023Article
- IMI 2023 Digest.Investigative ophthalmology & visual science · 2023Article
- Myopia Control Efficacy and Long-Term Safety of a Novel Orthokeratology Lens (MESOK Study)-A Randomized Controlled Clinical Trial Combining Clinical and Tear Proteomics Data.Journal of clinical medicine · 2023Article
- Additive effects of narrowband light and optical defocus on chick eye growth and refraction.Eye and vision (London, England) · 2023Article
- Comparing the effects of highly aspherical lenslets versus defocus incorporated multiple segment spectacle lenses on myopia control.Scientific reports · 2023Article
- Effect of atropine 0.01% on myopia control in children aged 6-13 years during the 2022 lockdown in Shanghai.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Myopia progression has been found to be worsening during the COVID-19 pandemic. It is important to control the rapid myopia progression in this period. Objective: To analyze the association of COVID-19-related lockdown measures with myopia progression in schoolchildren and to compare the performance of defocus incorporated multiple segments (DIMS) lens with that of single vision lens (SVL) treatment in reducing myopia progression. Design, Setting, and Participants: This cohort study involved an exploratory, prespecified, comparison of 2 independent longitudinal studies performed at the same institute beginning in 2019. Data from Hong Kong schoolchildren (aged 7-13 years) were gathered and analyzed. Data analysis was performed from June to July 2021. Exposure: Schoolchildren in study 1 wore a DIMS lens for 18 months, and those in study 2 wore a SVL for 24 months. Main Outcomes and Measures: Cycloplegic spherical equivalent refraction and axial length were measured. Studies 1 and 2 started before the start of lockdown measures and continued throughout the lockdown. In both studies, periods of fewer and more COVID-19-related lockdown measures were identified. Because COVID-19 lockdown caused deviations from the visit schedule, myopia progression was normalized to 12-month change, which were compared between DIMS and SVL groups, also during the periods with less and more lockdown time. Results: There were 115 participants (58 girls [50.4%]; mean [SD] age, 10.3 [1.5] years) in the DIMS group; their mean (SD) baseline refraction was -4.02 (1.46) D. There were 56 participants (29 girls [51.8%]; mean [SD] age, 10.8 [1.5] years) in the SVL group; their mean (SD) baseline refraction was -2.99 (1.06) D. After controlling for the covariates, DIMS treatment was significantly associated with 34% less axial elongation (0.19 mm [95% CI, 0.16 to 0.22 mm] vs 0.30 mm [95% CI, 0.25 to 0.35 mm]; P < .001) and 46% less myopic progression after 12 months (-0.31 D [95% CI, -0.39 to -0.23 D] vs -0.57 D [95% CI, -0.69 to -0.45 D]; P = .001) compared with SVL treatment. In both the DIMS and SVL groups, more lockdown time was associated with significantly more spherical equivalent refraction (-0.54 D [95% CI, -0.64 to 0.44 D] vs -0.34 D [95% CI, -0.44 to -0.25 D]; P = .01) and axial length (0.29 mm [95% CI, 0.25 to 0.32 mm] vs 0.20 mm [95% CI, 0.16 to 0.24 mm]; P = .001) compared with less lockdown time. No significant interaction between treatment type and lockdown time was observed. Conclusions and Relevance: In this exploratory analysis, myopia progressed more rapidly in schoolchildren during the period when there were more COVID-19-related lockdown measures. However, optical treatment with DIMS was significantly associated with slower myopia progression compared with SVL treatment during the lockdown period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.